Does the media favor MLYS or CTMX?

In the previous week, CytomX Therapeutics had 3 more articles in the media than Mineralys Therapeutics. MarketBeat recorded 11 mentions for CytomX Therapeutics and 8 mentions for Mineralys Therapeutics. CytomX Therapeutics' average media sentiment score of 1.24 beat Mineralys Therapeutics' score of 1.00 indicating that CytomX Therapeutics is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Mineralys Therapeutics 6 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive CytomX Therapeutics 8 Very Positive mention(s) 0 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Does the media prefer CTMX or ZLAB?

In the previous week, CytomX Therapeutics had 9 more articles in the media than Zai Lab. MarketBeat recorded 11 mentions for CytomX Therapeutics and 2 mentions for Zai Lab. CytomX Therapeutics' average media sentiment score of 1.24 beat Zai Lab's score of 0.00 indicating that CytomX Therapeutics is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment CytomX Therapeutics 8 Very Positive mention(s) 0 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Zai Lab 0 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Does the media prefer AGIO or CTMX?

In the previous week, Agios Pharmaceuticals had 19 more articles in the media than CytomX Therapeutics. MarketBeat recorded 30 mentions for Agios Pharmaceuticals and 11 mentions for CytomX Therapeutics. CytomX Therapeutics' average media sentiment score of 1.24 beat Agios Pharmaceuticals' score of 0.37 indicating that CytomX Therapeutics is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Agios Pharmaceuticals 8 Very Positive mention(s) 2 Positive mention(s) 6 Neutral mention(s) 3 Negative mention(s) 2 Very Negative mention(s) Neutral CytomX Therapeutics 8 Very Positive mention(s) 0 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Does the media refer more to CTMX or BHVN?

In the previous week, CytomX Therapeutics had 4 more articles in the media than Biohaven. MarketBeat recorded 11 mentions for CytomX Therapeutics and 7 mentions for Biohaven. CytomX Therapeutics' average media sentiment score of 1.24 beat Biohaven's score of 0.83 indicating that CytomX Therapeutics is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment CytomX Therapeutics 8 Very Positive mention(s) 0 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Biohaven 4 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Positive

Does the media prefer CTMX or SLS?

In the previous week, CytomX Therapeutics and CytomX Therapeutics both had 11 articles in the media. CytomX Therapeutics' average media sentiment score of 1.24 beat SELLAS Life Sciences Group's score of 0.95 indicating that CytomX Therapeutics is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment CytomX Therapeutics 8 Very Positive mention(s) 0 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive SELLAS Life Sciences Group 5 Very Positive mention(s) 3 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

CytomX Therapeutics (CTMX) Competitors

$3.10 0.00 (0.00%)

Closing price 07/31/2026 04:00 PM Eastern

Extended Trading

$3.10 +0.00 (+0.16%)

As of 07/31/2026 07:34 PM Eastern

Compare

CTMX vs. MLYS, ZLAB, AGIO, BHVN, and SLS

Should you buy CytomX Therapeutics stock or one of its competitors? MarketBeat compares CytomX Therapeutics with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with CytomX Therapeutics include Mineralys Therapeutics (MLYS), Zai Lab (ZLAB), Agios Pharmaceuticals (AGIO), Biohaven (BHVN), and SELLAS Life Sciences Group (SLS).

How does CytomX Therapeutics compare to Mineralys Therapeutics?

Mineralys Therapeutics (NASDAQ:MLYS) and CytomX Therapeutics (NASDAQ:CTMX) are both healthcare companies, but which is the superior investment? We will compare the two companies based on the strength of their valuation, institutional ownership, dividends, analyst recommendations, media sentiment, profitability, risk and earnings.

84.5% of Mineralys Therapeutics shares are held by institutional investors. Comparatively, 67.8% of CytomX Therapeutics shares are held by institutional investors. 18.9% of Mineralys Therapeutics shares are held by company insiders. Comparatively, 3.8% of CytomX Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock is poised for long-term growth.

Mineralys Therapeutics presently has a consensus target price of $49.33, indicating a potential upside of 93.31%. CytomX Therapeutics has a consensus target price of $12.10, indicating a potential upside of 290.32%. Given CytomX Therapeutics' stronger consensus rating and higher possible upside, analysts clearly believe CytomX Therapeutics is more favorable than Mineralys Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Mineralys Therapeutics	1 Sell rating(s)	1 Hold rating(s)	6 Buy rating(s)	0 Strong Buy rating(s)	2.63
CytomX Therapeutics	1 Sell rating(s)	0 Hold rating(s)	9 Buy rating(s)	2 Strong Buy rating(s)	3.00

Mineralys Therapeutics has a beta of 0.66, suggesting that its stock price is 34% less volatile than the broader market. Comparatively, CytomX Therapeutics has a beta of 2.12, suggesting that its stock price is 112% more volatile than the broader market.

In the previous week, CytomX Therapeutics had 3 more articles in the media than Mineralys Therapeutics. MarketBeat recorded 11 mentions for CytomX Therapeutics and 8 mentions for Mineralys Therapeutics. CytomX Therapeutics' average media sentiment score of 1.24 beat Mineralys Therapeutics' score of 1.00 indicating that CytomX Therapeutics is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Mineralys Therapeutics	6 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
CytomX Therapeutics	8 Very Positive mention(s)	0 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

CytomX Therapeutics has higher revenue and earnings than Mineralys Therapeutics. Mineralys Therapeutics is trading at a lower price-to-earnings ratio than CytomX Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Mineralys Therapeutics	N/A	N/A	-$154.65M	-$2.05	N/A
CytomX Therapeutics	$76.20M	6.92	-$17.37M	-$0.41	N/A

Mineralys Therapeutics has a net margin of 0.00% compared to CytomX Therapeutics' net margin of -166.40%. Mineralys Therapeutics' return on equity of -27.92% beat CytomX Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Mineralys Therapeutics	N/A	-27.92%	-26.98%
CytomX Therapeutics	-166.40%	-36.61%	-28.02%

Summary

CytomX Therapeutics beats Mineralys Therapeutics on 11 of the 16 factors compared between the two stocks.

How does CytomX Therapeutics compare to Zai Lab?

CytomX Therapeutics (NASDAQ:CTMX) and Zai Lab (NASDAQ:ZLAB) are both healthcare companies, but which is the better business? We will contrast the two companies based on the strength of their earnings, media sentiment, profitability, analyst recommendations, institutional ownership, dividends, valuation and risk.

CytomX Therapeutics has higher earnings, but lower revenue than Zai Lab. Zai Lab is trading at a lower price-to-earnings ratio than CytomX Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
CytomX Therapeutics	$76.20M	6.92	-$17.37M	-$0.41	N/A
Zai Lab	$460.16M	4.52	-$175.54M	-$1.62	N/A

In the previous week, CytomX Therapeutics had 9 more articles in the media than Zai Lab. MarketBeat recorded 11 mentions for CytomX Therapeutics and 2 mentions for Zai Lab. CytomX Therapeutics' average media sentiment score of 1.24 beat Zai Lab's score of 0.00 indicating that CytomX Therapeutics is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
CytomX Therapeutics	8 Very Positive mention(s)	0 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Zai Lab	0 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

CytomX Therapeutics has a beta of 2.12, indicating that its share price is 112% more volatile than the broader market. Comparatively, Zai Lab has a beta of 0.78, indicating that its share price is 22% less volatile than the broader market.

67.8% of CytomX Therapeutics shares are owned by institutional investors. Comparatively, 41.7% of Zai Lab shares are owned by institutional investors. 3.8% of CytomX Therapeutics shares are owned by insiders. Comparatively, 4.9% of Zai Lab shares are owned by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.

Zai Lab has a net margin of -39.29% compared to CytomX Therapeutics' net margin of -166.40%. Zai Lab's return on equity of -24.32% beat CytomX Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
CytomX Therapeutics	-166.40%	-36.61%	-28.02%
Zai Lab	-39.29%	-24.32%	-15.52%

CytomX Therapeutics currently has a consensus price target of $12.10, indicating a potential upside of 290.32%. Zai Lab has a consensus price target of $40.00, indicating a potential upside of 118.94%. Given CytomX Therapeutics' stronger consensus rating and higher possible upside, equities research analysts clearly believe CytomX Therapeutics is more favorable than Zai Lab.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
CytomX Therapeutics	1 Sell rating(s)	0 Hold rating(s)	9 Buy rating(s)	2 Strong Buy rating(s)	3.00
Zai Lab	1 Sell rating(s)	1 Hold rating(s)	4 Buy rating(s)	1 Strong Buy rating(s)	2.71

Summary

CytomX Therapeutics beats Zai Lab on 12 of the 17 factors compared between the two stocks.

How does CytomX Therapeutics compare to Agios Pharmaceuticals?

Agios Pharmaceuticals (NASDAQ:AGIO) and CytomX Therapeutics (NASDAQ:CTMX) are both small-cap healthcare companies, but which is the superior investment? We will compare the two businesses based on the strength of their institutional ownership, earnings, valuation, media sentiment, risk, profitability, analyst recommendations and dividends.

Agios Pharmaceuticals has a beta of 0.58, indicating that its stock price is 42% less volatile than the broader market. Comparatively, CytomX Therapeutics has a beta of 2.12, indicating that its stock price is 112% more volatile than the broader market.

Agios Pharmaceuticals presently has a consensus target price of $40.88, suggesting a potential upside of 36.16%. CytomX Therapeutics has a consensus target price of $12.10, suggesting a potential upside of 290.32%. Given CytomX Therapeutics' stronger consensus rating and higher possible upside, analysts clearly believe CytomX Therapeutics is more favorable than Agios Pharmaceuticals.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Agios Pharmaceuticals	1 Sell rating(s)	4 Hold rating(s)	5 Buy rating(s)	0 Strong Buy rating(s)	2.40
CytomX Therapeutics	1 Sell rating(s)	0 Hold rating(s)	9 Buy rating(s)	2 Strong Buy rating(s)	3.00

CytomX Therapeutics has a net margin of -166.40% compared to Agios Pharmaceuticals' net margin of -418.24%. Agios Pharmaceuticals' return on equity of -35.67% beat CytomX Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Agios Pharmaceuticals	-418.24%	-35.67%	-33.06%
CytomX Therapeutics	-166.40%	-36.61%	-28.02%

67.8% of CytomX Therapeutics shares are owned by institutional investors. 5.4% of Agios Pharmaceuticals shares are owned by company insiders. Comparatively, 3.8% of CytomX Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.

CytomX Therapeutics has higher revenue and earnings than Agios Pharmaceuticals. CytomX Therapeutics is trading at a lower price-to-earnings ratio than Agios Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Agios Pharmaceuticals	$54.03M	33.17	-$412.78M	-$7.01	N/A
CytomX Therapeutics	$76.20M	6.92	-$17.37M	-$0.41	N/A

In the previous week, Agios Pharmaceuticals had 19 more articles in the media than CytomX Therapeutics. MarketBeat recorded 30 mentions for Agios Pharmaceuticals and 11 mentions for CytomX Therapeutics. CytomX Therapeutics' average media sentiment score of 1.24 beat Agios Pharmaceuticals' score of 0.37 indicating that CytomX Therapeutics is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Agios Pharmaceuticals	8 Very Positive mention(s)	2 Positive mention(s)	6 Neutral mention(s)	3 Negative mention(s)	2 Very Negative mention(s)	Neutral
CytomX Therapeutics	8 Very Positive mention(s)	0 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Summary

CytomX Therapeutics beats Agios Pharmaceuticals on 12 of the 17 factors compared between the two stocks.

How does CytomX Therapeutics compare to Biohaven?

CytomX Therapeutics (NASDAQ:CTMX) and Biohaven (NYSE:BHVN) are both healthcare companies, but which is the better investment? We will contrast the two businesses based on the strength of their valuation, media sentiment, risk, earnings, analyst recommendations, dividends, institutional ownership and profitability.

Biohaven has a net margin of 0.00% compared to CytomX Therapeutics' net margin of -166.40%. CytomX Therapeutics' return on equity of -36.61% beat Biohaven's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
CytomX Therapeutics	-166.40%	-36.61%	-28.02%
Biohaven	N/A	-866.46%	-137.99%

CytomX Therapeutics currently has a consensus target price of $12.10, indicating a potential upside of 290.32%. Biohaven has a consensus target price of $21.63, indicating a potential upside of 60.26%. Given CytomX Therapeutics' stronger consensus rating and higher possible upside, research analysts plainly believe CytomX Therapeutics is more favorable than Biohaven.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
CytomX Therapeutics	1 Sell rating(s)	0 Hold rating(s)	9 Buy rating(s)	2 Strong Buy rating(s)	3.00
Biohaven	2 Sell rating(s)	4 Hold rating(s)	10 Buy rating(s)	2 Strong Buy rating(s)	2.67

CytomX Therapeutics has a beta of 2.12, meaning that its stock price is 112% more volatile than the broader market. Comparatively, Biohaven has a beta of 1.28, meaning that its stock price is 28% more volatile than the broader market.

In the previous week, CytomX Therapeutics had 4 more articles in the media than Biohaven. MarketBeat recorded 11 mentions for CytomX Therapeutics and 7 mentions for Biohaven. CytomX Therapeutics' average media sentiment score of 1.24 beat Biohaven's score of 0.83 indicating that CytomX Therapeutics is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
CytomX Therapeutics	8 Very Positive mention(s)	0 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Biohaven	4 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Positive

67.8% of CytomX Therapeutics shares are held by institutional investors. Comparatively, 88.8% of Biohaven shares are held by institutional investors. 3.8% of CytomX Therapeutics shares are held by insiders. Comparatively, 13.8% of Biohaven shares are held by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term.

CytomX Therapeutics has higher revenue and earnings than Biohaven. CytomX Therapeutics is trading at a lower price-to-earnings ratio than Biohaven, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
CytomX Therapeutics	$76.20M	6.92	-$17.37M	-$0.41	N/A
Biohaven	N/A	N/A	-$738.82M	-$5.67	N/A

Summary

CytomX Therapeutics beats Biohaven on 10 of the 15 factors compared between the two stocks.

How does CytomX Therapeutics compare to SELLAS Life Sciences Group?

CytomX Therapeutics (NASDAQ:CTMX) and SELLAS Life Sciences Group (NASDAQ:SLS) are both small-cap healthcare companies, but which is the better investment? We will compare the two businesses based on the strength of their media sentiment, earnings, analyst recommendations, dividends, valuation, institutional ownership, profitability and risk.

In the previous week, CytomX Therapeutics and CytomX Therapeutics both had 11 articles in the media. CytomX Therapeutics' average media sentiment score of 1.24 beat SELLAS Life Sciences Group's score of 0.95 indicating that CytomX Therapeutics is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
CytomX Therapeutics	8 Very Positive mention(s)	0 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
SELLAS Life Sciences Group	5 Very Positive mention(s)	3 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

67.8% of CytomX Therapeutics shares are held by institutional investors. Comparatively, 17.4% of SELLAS Life Sciences Group shares are held by institutional investors. 3.8% of CytomX Therapeutics shares are held by company insiders. Comparatively, 1.3% of SELLAS Life Sciences Group shares are held by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock is poised for long-term growth.

CytomX Therapeutics has a beta of 2.12, meaning that its share price is 112% more volatile than the broader market. Comparatively, SELLAS Life Sciences Group has a beta of 2.48, meaning that its share price is 148% more volatile than the broader market.

CytomX Therapeutics currently has a consensus target price of $12.10, indicating a potential upside of 290.32%. SELLAS Life Sciences Group has a consensus target price of $10.00, indicating a potential downside of 0.10%. Given CytomX Therapeutics' stronger consensus rating and higher probable upside, analysts plainly believe CytomX Therapeutics is more favorable than SELLAS Life Sciences Group.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
CytomX Therapeutics	1 Sell rating(s)	0 Hold rating(s)	9 Buy rating(s)	2 Strong Buy rating(s)	3.00
SELLAS Life Sciences Group	1 Sell rating(s)	0 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.33

SELLAS Life Sciences Group has a net margin of 0.00% compared to CytomX Therapeutics' net margin of -166.40%. CytomX Therapeutics' return on equity of -36.61% beat SELLAS Life Sciences Group's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
CytomX Therapeutics	-166.40%	-36.61%	-28.02%
SELLAS Life Sciences Group	N/A	-47.12%	-42.63%

CytomX Therapeutics has higher revenue and earnings than SELLAS Life Sciences Group. SELLAS Life Sciences Group is trading at a lower price-to-earnings ratio than CytomX Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
CytomX Therapeutics	$76.20M	6.92	-$17.37M	-$0.41	N/A
SELLAS Life Sciences Group	N/A	N/A	-$26.86M	-$0.23	N/A

Summary

CytomX Therapeutics beats SELLAS Life Sciences Group on 12 of the 15 factors compared between the two stocks.

Get CytomX Therapeutics News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding CTMX and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

CTMX vs. The Competition

Export

Metric	CytomX Therapeutics	Biotechnology Industry	Healthcare Sector	NASDAQ Exchange
Market Cap	$527.59M	$3.54B	$6.86B	$12.42B
Dividend Yield	N/A	3.78%	2.59%	10.03%
P/E Ratio	-7.56	7.38	282.27	24.66
Price / Sales	6.92	1,190.93	563.88	76.67
Price / Cash	N/A	44.80	28.60	46.71
Price / Book	5.34	16.79	10.93	6.07
Net Income	-$17.37M	-$12.56M	$3.49B	$347.99M
7 Day Performance	-4.62%	-1.79%	-0.61%	-0.42%
1 Month Performance	-18.85%	-8.42%	-3.75%	-4.80%
1 Year Performance	31.91%	48.61%	62.10%	18.61%

CytomX Therapeutics Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
CTMX CytomX Therapeutics	2.6284 of 5 stars	$3.10 flat	$12.10 +290.3%	+31.9%	$527.59M	$76.20M	N/A	170	News Coverage Positive News Upcoming Earnings Gap Up
MLYS Mineralys Therapeutics	3.6782 of 5 stars	$27.21 +1.9%	$49.33 +81.3%	+86.8%	$2.20B	N/A	N/A	28	Positive News
ZLAB Zai Lab	2.5559 of 5 stars	$18.64 -3.0%	$40.00 +114.6%	-50.4%	$2.19B	$460.16M	N/A	1,784	Upcoming Earnings
AGIO Agios Pharmaceuticals	2.7571 of 5 stars	$36.97 +1.7%	$40.00 +8.2%	-14.2%	$2.16B	$54.03M	N/A	390	Trending News Earnings Report Analyst Forecast Analyst Revision Gap Down
BHVN Biohaven	3.4001 of 5 stars	$14.50 +1.2%	$21.63 +49.2%	-8.6%	$2.16B	N/A	N/A	239	Upcoming Earnings Gap Up

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:CTMX) was last updated on 8/3/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

CytomX Therapeutics (CTMX) Competitors

CTMX vs. MLYS, ZLAB, AGIO, BHVN, and SLS

How does CytomX Therapeutics compare to Mineralys Therapeutics?

Summary

How does CytomX Therapeutics compare to Zai Lab?

Summary

How does CytomX Therapeutics compare to Agios Pharmaceuticals?

Summary

How does CytomX Therapeutics compare to Biohaven?

Summary

How does CytomX Therapeutics compare to SELLAS Life Sciences Group?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

CTMX vs. The Competition

CytomX Therapeutics Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

CytomX Therapeutics (CTMX) Competitors

CTMX vs. MLYS, ZLAB, AGIO, BHVN, and SLS

How does CytomX Therapeutics compare to Mineralys Therapeutics?

Do insiders & institutionals have more ownership in MLYS or CTMX?

Do analysts prefer MLYS or CTMX?

Which has more risk and volatility, MLYS or CTMX?

Does the media favor MLYS or CTMX?

Which has preferable earnings and valuation, MLYS or CTMX?

Is MLYS or CTMX more profitable?

Summary

How does CytomX Therapeutics compare to Zai Lab?

Which has higher earnings and valuation, CTMX or ZLAB?

Does the media prefer CTMX or ZLAB?

Which has more volatility and risk, CTMX or ZLAB?

Do insiders and institutionals believe in CTMX or ZLAB?

Is CTMX or ZLAB more profitable?

Do analysts rate CTMX or ZLAB?

Summary

How does CytomX Therapeutics compare to Agios Pharmaceuticals?

Which has more volatility & risk, AGIO or CTMX?

Do analysts rate AGIO or CTMX?

Is AGIO or CTMX more profitable?

Do insiders & institutionals hold more shares of AGIO or CTMX?

Which has stronger valuation & earnings, AGIO or CTMX?

Does the media prefer AGIO or CTMX?

Summary

How does CytomX Therapeutics compare to Biohaven?

Is CTMX or BHVN more profitable?

Do analysts rate CTMX or BHVN?

Which has more risk & volatility, CTMX or BHVN?

Does the media refer more to CTMX or BHVN?

Do institutionals & insiders hold more shares of CTMX or BHVN?

Which has stronger earnings & valuation, CTMX or BHVN?

Summary

How does CytomX Therapeutics compare to SELLAS Life Sciences Group?

Does the media prefer CTMX or SLS?

Do insiders and institutionals hold more shares of CTMX or SLS?

Which has more volatility and risk, CTMX or SLS?

Do analysts recommend CTMX or SLS?

Is CTMX or SLS more profitable?

Which has higher valuation and earnings, CTMX or SLS?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

CTMX vs. The Competition

CytomX Therapeutics Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools